Fidelity leads $97m Series C round in Chinese biopharma Antengene

Fidelity leads $97m Series C round in Chinese biopharma Antengene

Laboratory equipment. Photo: Pixabay

Antengene Corporation, a Chinese biopharma firm that develops therapies in the haematology and oncology fields, announced on Monday that it has closed $97 million in a Series C round of financing.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter